PPAR-γ Impairment Alters Peroxisome Functionality in Primary Astrocyte Cell Cultures
Figure 2
Restoration of catalase activity over time after treatment with GW9662. Astrocytes ( cells/well) were treated with the irreversible PPAR antagonist GW9662 (100 μM) for (a) 2 days in the absence or presence of the PPAR agonist rosiglitazone (10 μM). Cultures were continued for a further 2 or 5 days in the absence of GW9662 and in the absence or presence of rosiglitazone. Catalase activity was measured on days 0, 2, 4, and 7. (b) Cells were treated with GW9662 (100 μM) for 5 days in the absence or presence of the PPARγ agonist rosiglitazone (100 μM). Cultures were allowed for further 2 or 5 days in the absence of GW9662 and in the absence or presence of Rosiglitazone. Catalase activity was measured on days 0, 5, 7, and 10. Values are expressed as the mean ± S.E.M. percent of control of three experiments. Control catalase activity (day 0) was arbitrarily set as 100%. * in comparison to control conditions in the absence of treatment on day 0; in comparison to control on days 2 (a) or 5 (b).
